Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alzheimer's Drug Discovery Foundation (Addf)
Headquarters: New York, NY, United States of America
Website: http://www.alzdiscovery.org
Year Founded: 1998
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 27, 2023
Finance
April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies
Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
BioCentury | Jan 27, 2022
Data Byte
Alzheimer’s foundation award roundup
Funding for Wave’s stereopure ASO, Optina’s awAIr cerebral amyloid status test
BioCentury | Sep 28, 2021
Product Development
Alzheimer’s blood markers promise new era of clinical trials
Sensitive technologies could relieve dependence on imaging, but agreement on standards will be key
BioCentury | Mar 14, 2020
Politics, Policy & Law
Patient access to new Alzheimer’s drugs will depend on diagnostic innovation and payment reform
With Biogen’s Alzheimer’s therapy up for approval this year, there’s an urgency to solve market access
BioCentury | May 4, 2019
Product Development
How the amyloid hypothesis holds its grip
Why pharmas can’t let go of the amyloid hypothesis of Alzheimer’s disease
BioCentury | May 4, 2019
Product Development
Amyloid: how did we get here and what can we learn?
Lessons for industry from nearly 20 years of amyloid failures
BioCentury | Apr 11, 2019
Company News
ADDF expands Alzheimer's diagnostic accelerator into digital space
BioCentury | Feb 15, 2019
Product R&D
A bug about Alzheimer’s
Cortexyme offers a new MOA in Alzheimer’s, faces down skeptics
BioCentury | Jan 19, 2018
Strategy
After amyloid
How the Alzheimer’s disease community is moving past amyloid
BioCentury | Jun 30, 2016
Targets & Mechanisms
AChE revisited
Why Neuro-Bio thinks it's time to revisit the role of AChE in AD
Items per page:
1 - 10 of 20